TB-003 Apheresis Platelets - US Guidance v1.0.0 – PDF
This document provides information regarding ICCBBA’s current understanding for labeling Apheresis Platelets in the US. In addition, the document addresses items not covered in the United States Industry Consensus Standard for the Uniform Labeling of Blood and Blood Components Using ISBT 128, Version 3.0.0.
TB-004 ISBT 128 and Traceability v1.5.0 – PDF
This document provides information on how ISBT 128 supports traceability through the combined use of a globally unique Donation Identification Number (DIN) and a Product Code.
This document provides information regarding the ISBT 128 Donation Identification Number (DIN). In addition, the document provides a brief description on Flag Characters and the Check Character.
TB-012 ISBT 128 Implementation Plan v1.0.0 – PDF
This example plan was meant to be comprehensive, and not all steps may be needed by all facilities. Therefore, facilities should use it as a guide or checklist of things to consider rather than attempting to follow it precisely.
The purpose of this document is to provide guidance to users on the changes made to the tissues terminology in version 7.35 of the ISBT 128 Standard Terminology for Medical Products of Human Origin (ST-002).
TB-014 - Revised Reproductive Terminology v1.0.0 - PDF
The purpose of this document is to provide guidance to users on the changes made to the Reproductive Terminology in version 7.32 of the ISBT 128 Standard Terminology for Medical Products of Human Origin (ST-002).
The purpose of this interim guidance is to assist US based blood facilities in the selection of the correct labels for labeling platelets in the US based on the FDA Guidance: Bacterial Risk Control Strategies for Blood Collection Establishment and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion (September 2019).
ICCBBA has published a new technical bulletin, TB-016 Improving Quality of Care through Traceability, to describe how the use of ISBT 128 facilitates the inclusion of product identifiers into patient electronic health records. Developments described within this document would have an immediate beneficial impact on traceability and would facilitate the electronic exchange of health information to improve quality of care for patients around the world.